Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors
Status:
Completed
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test whether perifosine- a drug that inhibits the protein
AKT, and has had some success in the treatment of adult cancers- is safe and effective in
treating cancer. The investigators want to find out what effects, good and/or bad, it has on
the patient and the cancer. The investigators are testing different dose schedules of
perifosine and the patient will be asked to partake in one of the dose schedules.
Phase:
Phase 1
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborators:
AEterna Zentaris Duke University University of Wisconsin, Madison